• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $24 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-26 Mln

Lumos Pharma Inc. (LUMO) Share Price

$3.00

As on 04-Mar-2024 15:57 EST

$0.000.00%

  • Prev Close info

    $3.00

  • Day's Openinfo

    $3.03

  • Today's Highinfo

    $3.05

  • Today's Lowinfo

    $3.02

  • Today's Volumeinfo

    8,732

  • 52 Week rangeinfo

    $2.63 - 4.55

Please wait...

Lumos Pharma Inc. (LUMO) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Lumos Pharma (LUMO)
-5.66 0.33 -1.32 -14.04 -40.54 -28.63 -37.90
S&P BSE Sensex*
1.99 2.21 6.99 23.19 13.16 15.36 13.26
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 04-Mar-2024  |  *As on 05-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Lumos Pharma (LUMO)
-11.91 -47.91 -80.59 56.83 66.45 -81.09 -21.11
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Lumos Pharma Inc. (LUMO) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Lumos Pharma Inc. (LUMO)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Lumos Pharma Inc. (LUMO)

        Founder, CEO & Chairman

        Mr. Richard J. Hawkins

        Chief Scientific Officer & President

        Dr. John C. McKew Ph.D.

        Headquarters

        Austin, TX

        FAQs for Lumos Pharma Inc. (LUMO)

        The total asset value of Lumos Pharma Inc. (LUMO) stood at $ 54 Mln as on 30-Sep-23

        The share price of Lumos Pharma Inc. (LUMO) is $3.00 (NASDAQ) as of 04-Mar-2024 15:57 EST. Lumos Pharma Inc. (LUMO) has given a return of -40.54% in the last 3 years.

        Lumos Pharma Inc. (LUMO) has a market capitalisation of $ 24 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Lumos Pharma Inc. (LUMO) is 0.68 times as on 29-Feb-2024, a -0.77% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Lumos Pharma Inc. (LUMO) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Lumos Pharma Inc. (LUMO) and enter the required number of quantities and click on buy to purchase the shares of Lumos Pharma Inc. (LUMO).

        Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas. Address: 4200 Marathon Boulevard, Austin, TX, United States, 78756

        The CEO & director of Mr. Richard J. Hawkins. is Lumos Pharma Inc. (LUMO), and CFO & Sr. VP is Dr. John C. McKew Ph.D..

        The promoters of Lumos Pharma Inc. (LUMO) have pledged 0% of the total equity as on Sep-23.

        Lumos Pharma Inc. (LUMO) Ratios
        Return on equity(%)
        -71.72
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Lumos Pharma Inc. (LUMO) was $-26 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $24.14 Mln
        • Revenue (TTM)revenue-information $1.74 Mln
        • Earnings (TTM) earning-information $-26.11 Mln
        • Cash date-information $42.69 Mln
        • Total Debt info $0.27 Mln
        • Insider's Holding 35.39%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $2.63 - 4.55
        • Shares outstanding share-outstanding 7,914,580
        • 10 Years Aggregate:

          CFO: $-206.19 Mln

          EBITDA: $-265.78 Mln

          Net Profit: $-291.19 Mln

        About The Company

        • IPO Date 11-Nov-2011
        • Founder, CEO & Chairman Mr. Richard J. Hawkins
        • Chief Scientific Officer & President Dr. John C. McKew Ph.D.
        • Listing key-listing NASDAQ: LUMO
        • Country United States
        • Headquarters headquarters Austin, TX
        • Website website https://lumos-pharma.com
        • Business

          Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in...  Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas. Address: 4200 Marathon Boulevard, Austin, TX, United States, 78756  Read more

        share-fund-plan-icon